166 filings
Page 3 of 9
6-K
9wc0v oxsqlw82jb3omq
11 Jan 22
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
8:15am
6-K
9g8u7e7xap ls
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
xse4f2
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
qmsy28 jc
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
g7y o6jvp
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
tvdye75a
31 Aug 21
Current report (foreign)
4:30pm
6-K
avci5j4fjczvf7ie0i
23 Aug 21
Current report (foreign)
4:30pm
6-K
3itw3ntlvz
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
ju7 up0d1y7
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
iykh z40o1exoa
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
8acxn3 9gvu5xwula14k
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
zewxicbu
19 Jul 21
Current report (foreign)
4:30pm
6-K
scujfr06
2 Jul 21
Current report (foreign)
4:30pm
6-K
cufou oks3
13 May 21
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
8:13am
6-K
zffv d78rk5bpb1e7u
3 May 21
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis
8:42am
6-K
sgzrfrw7
26 Mar 21
Current report (foreign)
5:11pm
6-K
4l8g5t
18 Mar 21
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
7:29am
6-K
wwzj0rv
16 Mar 21
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
8:38am
6-K
b5vf1kdf1vx efhz
18 Feb 21
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
9:26am
6-K
ju17f417
16 Feb 21
Current report (foreign)
4:26pm